Hub : Traits :

Medication for cholesterol, blood pressure or diabetes

91 significantly associated models · 33 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 5988926 7460433 2 1 1.8e-07 4.4e-07 3.8e-01 97 DNAJC11
2 1 11060075 12600396 2 1 3.2e-08 9.6e-11 7.3e-04 73 CLCN6
3 1 109098737 110733794 3 1 3.9e-20 3.2e-20 1.0e+00 100 PSRC1
4 2 20529948 21958745 1 1 4.7e-09 1.2e-09 1.7e-02 85 APOB
5 2 43342098 44759941 1 1 5.4e-08 2.1e-11 1.5e-08 29 ABCG5
6 3 26720690 28211713 1 2 2.4e-07 8.8e-08 1.0e-01 91 SLC4A7
7 5 126596610 128116643 1 1 3.3e-07 1.3e-09 2.6e-04 64 CTC-228N24.3
8 7 99122437 100516003 1 1 9.7e-08 2.1e-06 9.7e-01 100 PVRIG
9 11 99859184 101559718 2 1 5.5e-14 1.3e-13 1.8e-01 97 TMEM133
10 11 110721187 112295421 2 1 7.7e-10 6.1e-10 1.0e+00 100 SIK2
11 11 115953897 117745003 2 2 4.7e-14 4.1e-15 6.5e-01 100 PAFAH1B2 ZNF259
12 12 89286081 90799212 1 1 1.1e-07 3.1e-09 8.3e-03 80 ATP2B1
13 12 111154626 112582540 1 1 2.0e-07 1.2e-10 5.4e-05 61 SH2B3
14 15 74042497 75930199 3 1 4.6e-08 4.5e-08 2.3e-01 95 CSK
15 15 90712555 92135418 2 1 6.0e-17 1.1e-15 1.0e+00 100 FES
16 16 69323837 70794031 1 1 3.7e-07 1.3e-05 5.1e-04 36 PDXDC2
17 17 60858059 62279811 1 1 5.7e-10 9.7e-10 1.4e-01 94 ACE
18 19 10793749 12191233 1 1 2.9e-07 1.8e-14 3.0e-09 40 EPOR
19 20 30083621 31469577 1 1 9.0e-08 7.3e-06 1.9e-01 92 TSPY26P
20 20 61989111 62912463 4 1 3.7e-10 5.5e-09 1.7e-01 94 RGS19

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (in father) 2.06 1 0 0.0 0.00 1.0e+00 ACE
Alzheimer’s Disease (including proxy) 2.61 2 1 3.0 0.00 1.0e+00 ACE PVRIG
Crohns Disease (2017) 1.49 2 0 0.0 0.00 1.0e+00 FES TSPY26P
Irritable Bowel Disease (IBD) 1.77 3 0 0.0 0.00 1.0e+00 FES RGS19 SH2B3
Ulcerative Colitis (UC) 1.66 1 0 0.0 0.00 1.0e+00 RGS19
Major Depression (MDD) 2.12 1 0 0.0 0.00 1.0e+00 FES
Reaction Time 2.06 1 1 3.0 0.00 1.0e+00 SH2B3
Breast Cancer 5.76 5 1 3.0 0.06 9.1e-01 CSK FES RGS19 SIK2 SLC4A7
Coronary Artery Disease (CAD) 5.60 4 2 6.1 0.96 4.5e-02 EPOR PSRC1 SH2B3 ZNF259
HDL Cholesterol 5.25 3 1 3.0 0.00 1.0e+00 APOB PSRC1 ZNF259
LDL Cholesterol 47.54 8 5 15.2 0.75 3.4e-02 ABCG5 APOB CSK EPOR PAFAH1B2 PSRC1 SH2B3 ZNF259
Lupus 1.61 1 0 0.0 0.00 1.0e+00 CSK
Primary Biliary Cirrhosis 2.25 2 1 3.0 0.00 1.0e+00 EPOR SH2B3
Rheumatoid Arthritis 2.19 2 0 0.0 0.00 1.0e+00 RGS19 SH2B3
Schizophrenia 1.59 1 1 3.0 0.00 1.0e+00 FES
Triglycerides 28.03 3 3 9.1 0.00 1.0e+00 APOB PAFAH1B2 ZNF259
Ulcerative Colitis 1.67 1 0 0.0 0.00 1.0e+00 PAFAH1B2
Blood Eosinophil Count 9.37 7 4 12.1 0.46 3.0e-01 CTC-228N24.3 EPOR PAFAH1B2 SH2B3 SIK2 TSPY26P ZNF259
Blood Platelet Count 2.59 7 4 12.1 -0.33 4.3e-01 CLCN6 CSK PAFAH1B2 SH2B3 SIK2 SLC4A7 ZNF259
Blood Red Count 2.44 8 4 12.1 0.38 3.6e-01 CLCN6 CSK CTC-228N24.3 FES PDXDC2 PVRIG SH2B3 TSPY26P
Blood White Count 4.78 8 2 6.1 0.60 1.1e-01 EPOR FES PAFAH1B2 RGS19 SH2B3 SLC4A7 TMEM133 TSPY26P
Heel T-Score 1.21 5 2 6.1 0.62 2.7e-01 APOB DNAJC11 PSRC1 SLC4A7 TMEM133
BMI 2.37 6 5 15.2 0.11 8.3e-01 CLCN6 CSK DNAJC11 PDXDC2 RGS19 TSPY26P
Height 1.20 12 8 24.2 -0.52 7.0e-02 ABCG5 ACE CTC-228N24.3 EPOR FES PDXDC2 PSRC1 RGS19 SH2B3 SLC4A7 TMEM133 ZNF259
Waist Hip Ratio (WHR) 1.61 2 1 3.0 0.00 1.0e+00 RGS19 SIK2
Systolic Blood Pressure 19.25 17 12 36.4 0.89 6.0e-07 ABCG5 ACE ATP2B1 CLCN6 CSK CTC-228N24.3 DNAJC11 EPOR FES PAFAH1B2 PDXDC2 RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P
Smoking Status 1.49 1 0 0.0 0.00 1.0e+00 FES
Allergy or Eczema 2.33 4 1 3.0 -0.43 5.7e-01 CLCN6 CSK SH2B3 SIK2
Cardiovascular Disease 21.88 21 20 60.6 0.97 6.2e-14 ABCG5 ACE APOB ATP2B1 CLCN6 CSK CTC-228N24.3 DNAJC11 EPOR FES PAFAH1B2 PDXDC2 PSRC1 PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P ZNF259
Hypothyroidism (self reported) 5.84 1 1 3.0 0.00 1.0e+00 SH2B3
Respiratory disease 1.23 2 0 0.0 0.00 1.0e+00 FES SIK2
Type 2 Diabetes (T2D) 3.07 3 1 3.0 0.00 1.0e+00 ACE PDXDC2 SH2B3
Lung FEV1/FVC ratio 2.46 6 5 15.2 0.05 9.2e-01 ATP2B1 DNAJC11 PSRC1 PVRIG TMEM133 TSPY26P
Lung FVC 1.39 5 1 3.0 -0.41 5.0e-01 CTC-228N24.3 PVRIG RGS19 SH2B3 TSPY26P
Hair Pigment 0.61 7 5 15.2 -0.52 2.3e-01 ATP2B1 EPOR FES RGS19 SH2B3 TMEM133 TSPY26P
Tanning 0.45 5 1 3.0 0.63 2.6e-01 CSK EPOR SH2B3 TMEM133 TSPY26P
Hand grip strength (left) 1.44 2 0 0.0 0.00 1.0e+00 ABCG5 PDXDC2
Number of treatments/medications taken 6.28 8 3 9.1 -0.97 6.6e-05 ABCG5 ACE FES PSRC1 SH2B3 SLC4A7 TMEM133 TSPY26P
Sensitivity / hurt feelings 1.35 1 0 0.0 0.00 1.0e+00 FES
Other serious medical condition/disability diagnosed by doctor 1.53 1 0 0.0 0.00 1.0e+00 CSK
Systolic blood pressure, automated reading 12.61 12 7 21.2 -0.95 7.1e-07 ATP2B1 CLCN6 CSK CTC-228N24.3 DNAJC11 FES PDXDC2 RGS19 SH2B3 SIK2 SLC4A7 TMEM133
Angina 6.85 5 2 6.1 -0.99 1.4e-03 ABCG5 FES PSRC1 RGS19 TMEM133
Medication: Metformin 2.28 2 0 0.0 0.00 1.0e+00 ABCG5 PDXDC2
Pack years adult smoking proportion 1.30 1 0 0.0 0.00 1.0e+00 PDXDC2
Impedance of leg (right) 2.60 6 3 9.1 -0.46 3.6e-01 CTC-228N24.3 FES PDXDC2 RGS19 SIK2 TMEM133
Leg fat-free mass (left) 1.82 7 1 3.0 0.71 7.2e-02 CTC-228N24.3 EPOR FES RGS19 SH2B3 SLC4A7 TMEM133
Trunk fat percentage 1.88 5 1 3.0 -0.42 4.8e-01 ACE CLCN6 DNAJC11 PDXDC2 SLC4A7
Hand grip strength (right) 1.70 2 1 3.0 0.00 1.0e+00 ABCG5 PDXDC2
Fed-up feelings 1.63 1 1 3.0 0.00 1.0e+00 SH2B3
Relative age voice broke 1.16 1 0 0.0 0.00 1.0e+00 PDXDC2
Taking other prescription medications 2.46 1 1 3.0 0.00 1.0e+00 SH2B3
Age when periods started (menarche) 1.50 2 1 3.0 0.00 1.0e+00 PDXDC2 PVRIG
Heel bone mineral density (BMD) T-score, automated (left) 1.21 2 0 0.0 0.00 1.0e+00 DNAJC11 TMEM133
Serious illness, injury or assault to yourself 1.59 1 0 0.0 0.00 1.0e+00 PDXDC2
High blood pressure 17.26 16 12 36.4 -0.97 1.6e-10 ABCG5 ACE ATP2B1 CLCN6 CSK CTC-228N24.3 DNAJC11 FES PDXDC2 PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P
Hayfever, allergic rhinitis or eczema 2.41 2 1 3.0 0.00 1.0e+00 CSK SIK2
Stomach or abdominal pain in last month 1.80 1 0 0.0 0.00 1.0e+00 PVRIG
Supplements: Glucosamine 1.76 1 0 0.0 0.00 1.0e+00 CSK
Medication: Atenolol 7.67 4 2 6.1 -0.98 2.3e-02 FES PSRC1 SH2B3 TMEM133
Medication: Levothyroxine sodium 4.86 1 1 3.0 0.00 1.0e+00 SH2B3
Sitting height 1.10 3 2 6.1 -0.59 4.1e-01 FES PDXDC2 SLC4A7
High blood pressure (mother) 8.34 6 2 6.1 -0.97 3.0e-04 CLCN6 CSK DNAJC11 FES SLC4A7 TMEM133
Body mass index (BMI) 2.11 5 1 3.0 -0.35 5.6e-01 CLCN6 DNAJC11 PDXDC2 RGS19 TSPY26P
Impedance of leg (left) 2.80 8 3 9.1 -0.37 3.7e-01 CTC-228N24.3 FES PDXDC2 PVRIG RGS19 SIK2 SLC4A7 TMEM133
Leg predicted mass (left) 1.82 5 1 3.0 0.96 1.0e-02 CTC-228N24.3 EPOR RGS19 SH2B3 TMEM133
Trunk fat mass 1.57 3 1 3.0 0.00 1.0e+00 CLCN6 DNAJC11 PDXDC2
Waist circumference 2.05 5 2 6.1 -0.26 6.7e-01 CLCN6 CSK DNAJC11 PDXDC2 TSPY26P
Past tobacco smoking 1.75 1 0 0.0 0.00 1.0e+00 SH2B3
Alcohol usually taken with meals 1.12 1 0 0.0 0.00 1.0e+00 FES
Nervous feelings 1.19 2 0 0.0 0.00 1.0e+00 PDXDC2 TSPY26P
Hearing difficulty/problems with background noise 1.91 1 0 0.0 0.00 1.0e+00 CSK
Had menopause 1.44 1 0 0.0 0.00 1.0e+00 DNAJC11
Had other major operations 2.27 1 0 0.0 0.00 1.0e+00 RGS19
Forced vital capacity (FVC) 1.46 5 1 3.0 0.97 6.2e-03 ABCG5 CTC-228N24.3 EPOR PDXDC2 TMEM133
Heel bone mineral density (BMD) T-score, automated (right) 1.06 2 0 0.0 0.00 1.0e+00 DNAJC11 TMEM133
Heart attack 4.76 3 1 3.0 0.00 1.0e+00 FES PSRC1 SH2B3
Allergy 2.48 1 1 3.0 0.00 1.0e+00 SIK2
Diabetes (self-reported) 2.79 3 1 3.0 0.00 1.0e+00 ACE DNAJC11 PDXDC2
Medication: Ramipril 6.86 5 2 6.1 -0.97 6.2e-03 CSK FES SH2B3 SIK2 TMEM133
Medication: Simvastatin 19.32 13 7 21.2 -0.92 7.4e-06 ABCG5 APOB DNAJC11 EPOR FES PAFAH1B2 PDXDC2 PSRC1 PVRIG RGS19 SIK2 TMEM133 ZNF259
Illnesses of siblings 5.49 5 0 0.0 0.99 2.2e-03 CLCN6 FES SH2B3 TMEM133 TSPY26P
Neuroticism score 0.89 1 0 0.0 0.00 1.0e+00 PDXDC2
Weight 1.48 6 0 0.0 0.03 9.5e-01 CLCN6 DNAJC11 EPOR PDXDC2 SH2B3 TSPY26P
Impedance of arm (right) 1.43 4 0 0.0 0.14 8.2e-01 RGS19 SH2B3 SLC4A7 TSPY26P
Arm fat percentage (right) 2.38 4 1 3.0 -0.54 4.6e-01 ACE CLCN6 DNAJC11 PDXDC2
Trunk fat-free mass 1.86 6 3 9.1 0.49 2.6e-01 CTC-228N24.3 EPOR PSRC1 SH2B3 SLC4A7 TMEM133
Hip circumference 1.91 5 3 9.1 0.24 7.0e-01 CLCN6 DNAJC11 PDXDC2 RGS19 SH2B3
Father's age at death 4.37 4 2 6.1 0.99 1.5e-02 CSK FES PSRC1 SH2B3
Worrier / anxious feelings 1.25 2 0 0.0 0.00 1.0e+00 PDXDC2 TSPY26P
Frequency of tiredness / lethargy in last 2 weeks 1.43 1 0 0.0 0.00 1.0e+00 SH2B3
Forced expiratory volume in 1-second (FEV1) 1.61 5 0 0.0 0.99 1.3e-03 CTC-228N24.3 EPOR PDXDC2 TMEM133 TSPY26P
Pulse rate 1.85 1 0 0.0 0.00 1.0e+00 PVRIG
Qualifications: A levels/AS levels or equivalent 0.63 1 0 0.0 0.00 1.0e+00 CSK
Asthma 1.65 1 1 3.0 0.00 1.0e+00 SIK2
Medication: Ibuprofen (e.g. Nurofen) 1.52 1 0 0.0 0.00 1.0e+00 CSK
Medication: Cholesterol lowering 25.13 17 9 27.3 -0.91 5.3e-07 ABCG5 ACE APOB CLCN6 CSK DNAJC11 EPOR FES PAFAH1B2 PDXDC2 PSRC1 PVRIG RGS19 SIK2 TMEM133 TSPY26P ZNF259
Medication: Lansoprazole 1.37 1 0 0.0 0.00 1.0e+00 SH2B3
Illnesses of mother 5.56 4 1 3.0 0.99 1.3e-02 ABCG5 FES SLC4A7 TMEM133
Forced expiratory volume in 1-second (FEV1), Best measure 1.67 6 0 0.0 0.98 8.4e-04 ABCG5 CTC-228N24.3 EPOR PDXDC2 TMEM133 TSPY26P
Impedance of arm (left) 1.51 4 0 0.0 0.08 8.9e-01 RGS19 SH2B3 SLC4A7 TSPY26P
Arm fat mass (right) 1.94 3 1 3.0 0.00 1.0e+00 CLCN6 DNAJC11 PDXDC2
Trunk predicted mass 1.85 6 3 9.1 0.50 2.5e-01 CTC-228N24.3 EPOR PSRC1 SH2B3 SLC4A7 TMEM133
Standing height 1.16 7 3 9.1 0.59 1.2e-01 ABCG5 CTC-228N24.3 EPOR PDXDC2 PSRC1 SH2B3 SLC4A7
Breastfed as a baby 1.09 1 0 0.0 0.00 1.0e+00 FES
Hair/balding pattern: Pattern 4 0.77 1 0 0.0 0.00 1.0e+00 FES
Birth weight of first child 5.94 6 3 9.1 0.97 1.2e-03 CLCN6 CSK CTC-228N24.3 FES RGS19 SH2B3
Blood clot in the leg (DVT) 1.33 1 0 0.0 0.00 1.0e+00 SH2B3
Headache pain in last month 1.63 1 0 0.0 0.00 1.0e+00 FES
Gout (self-reported) 2.14 1 0 0.0 0.00 1.0e+00 SH2B3
Hypothyroidism/myxoedema (self-reported) 5.07 1 1 3.0 0.00 1.0e+00 SH2B3
Medication: Amlodipine 7.01 6 2 6.1 -0.99 1.5e-05 ATP2B1 CLCN6 FES SLC4A7 TMEM133 TSPY26P
Birth weight 3.43 4 3 9.1 1.00 4.8e-03 CLCN6 FES SH2B3 SIK2
Chronic bronchitis/emphysema (mother) 2.26 1 0 0.0 0.00 1.0e+00 SIK2
High blood pressure (siblings) 6.40 6 2 6.1 -0.98 6.7e-04 ATP2B1 CLCN6 FES SH2B3 SLC4A7 TMEM133
Forced vital capacity (FVC), Best measure 1.54 4 1 3.0 1.00 4.3e-03 ABCG5 CTC-228N24.3 EPOR PDXDC2
Body fat percentage 2.21 5 2 6.1 -0.45 4.5e-01 ACE CLCN6 DNAJC11 PDXDC2 SLC4A7
Leg fat percentage (right) 2.77 5 3 9.1 -0.69 2.0e-01 CLCN6 CTC-228N24.3 DNAJC11 PDXDC2 TSPY26P
Arm fat-free mass (right) 1.68 6 1 3.0 0.31 5.0e-01 EPOR PSRC1 RGS19 SH2B3 SLC4A7 TSPY26P
Exposure to tobacco smoke outside home 0.94 1 0 0.0 0.00 1.0e+00 SH2B3
Comparative body size at age 10 1.24 2 0 0.0 0.00 1.0e+00 DNAJC11 PDXDC2
Wheeze or whistling in the chest in last year 1.87 1 1 3.0 0.00 1.0e+00 SIK2
Medication for pain relief, constipation, heartburn 1.36 1 0 0.0 0.00 1.0e+00 ACE
Medication: Blood pressure 17.39 16 12 36.4 -0.98 2.9e-12 ABCG5 ACE ATP2B1 CLCN6 CSK CTC-228N24.3 DNAJC11 FES PDXDC2 PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P
Angina (self-reported) 7.00 5 2 6.1 -0.98 3.4e-03 ABCG5 FES PSRC1 RGS19 TMEM133
Medication: Allopurinol 1.78 1 0 0.0 0.00 1.0e+00 SH2B3
Mean time to correctly identify matches 2.72 2 1 3.0 0.00 1.0e+00 FES SH2B3
Heart disease (mother) 4.34 2 0 0.0 0.00 1.0e+00 ABCG5 FES
Whole body fat mass 1.76 4 1 3.0 -0.56 4.4e-01 CLCN6 DNAJC11 PDXDC2 TSPY26P
Leg fat mass (right) 1.98 4 2 6.1 -0.61 3.9e-01 CLCN6 DNAJC11 PDXDC2 TSPY26P
Arm predicted mass (right) 1.69 6 1 3.0 0.29 5.3e-01 EPOR PSRC1 RGS19 SH2B3 SLC4A7 TSPY26P
Pulse rate, automated reading 2.47 4 2 6.1 -0.15 8.5e-01 APOB PDXDC2 PVRIG SIK2
Alcohol intake frequency. 1.07 1 0 0.0 0.00 1.0e+00 PDXDC2
Comparative height size at age 10 1.02 2 1 3.0 0.00 1.0e+00 PSRC1 SH2B3
Overall health rating 1.97 2 0 0.0 0.00 1.0e+00 ABCG5 TSPY26P
Medication: Aspirin 7.08 6 1 3.0 -1.00 9.5e-06 EPOR FES PSRC1 RGS19 SH2B3 SIK2
Hypertension (Self-reported) 17.47 16 14 42.4 -0.97 6.6e-11 ABCG5 ACE ATP2B1 CLCN6 CSK CTC-228N24.3 DNAJC11 FES PDXDC2 PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P
Illnesses of father: Heart disease 7.59 7 2 6.1 -1.00 4.4e-07 ABCG5 EPOR FES PSRC1 RGS19 SH2B3 SIK2
Smoking status: Previous 1.64 1 0 0.0 0.00 1.0e+00 SH2B3
Whole body fat-free mass 1.81 7 3 9.1 0.56 1.5e-01 CTC-228N24.3 EPOR PSRC1 RGS19 SH2B3 SLC4A7 TMEM133
Leg fat-free mass (right) 1.87 8 1 3.0 0.72 4.3e-02 CTC-228N24.3 EPOR FES PSRC1 RGS19 SH2B3 SLC4A7 TMEM133
Arm fat percentage (left) 2.36 4 2 6.1 -0.56 4.4e-01 ACE CLCN6 DNAJC11 PDXDC2
Average weekly red wine intake 1.23 1 0 0.0 0.00 1.0e+00 CSK
Loneliness, isolation 1.46 1 0 0.0 0.00 1.0e+00 SH2B3
Ever had bowel cancer screening 1.30 1 0 0.0 0.00 1.0e+00 SIK2
Diabetes diagnosed by doctor 3.27 3 1 3.0 0.00 1.0e+00 ACE PDXDC2 SH2B3
Ever had stillbirth, spontaneous miscarriage or termination 1.33 1 0 0.0 0.00 1.0e+00 FES
Qualifications: nursing, teaching 0.86 1 0 0.0 0.00 1.0e+00 SH2B3
Mouth/teeth dental problems: Mouth ulcers 1.48 2 0 0.0 0.00 1.0e+00 SH2B3 SLC4A7
Medication for cholesterol 7.11 6 3 9.1 0.99 2.8e-04 ACE PAFAH1B2 PSRC1 SH2B3 TMEM133 TSPY26P
Back pain experienced in last month 2.74 3 0 0.0 0.00 1.0e+00 APOB ATP2B1 SH2B3
Breast cancer (self-reported) 3.43 1 1 3.0 0.00 1.0e+00 SLC4A7
Asthma (self-reported) 1.51 1 1 3.0 0.00 1.0e+00 SIK2
Osteoarthritis (self-reported) 2.39 2 0 0.0 0.00 1.0e+00 CSK SIK2
Medication: Aspirin 7.55 6 2 6.1 -1.00 3.3e-06 EPOR FES PSRC1 RGS19 SH2B3 SIK2
Illnesses of father: None of the above (group 1) 5.29 3 1 3.0 0.00 1.0e+00 ABCG5 FES SH2B3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.45 2 0 0.0 0.00 1.0e+00 CTC-228N24.3 TMEM133
Whole body water mass 1.78 8 2 6.1 0.48 1.9e-01 CTC-228N24.3 EPOR PSRC1 RGS19 SH2B3 SLC4A7 TMEM133 TSPY26P
Leg predicted mass (right) 1.87 8 1 3.0 0.72 4.4e-02 CTC-228N24.3 EPOR FES PSRC1 RGS19 SH2B3 SLC4A7 TMEM133
Arm fat mass (left) 1.89 4 1 3.0 -0.57 4.3e-01 CLCN6 DNAJC11 PDXDC2 TSPY26P
Number of self-reported non-cancer illnesses 6.20 7 1 3.0 -0.98 1.7e-04 ABCG5 CLCN6 PDXDC2 RGS19 SH2B3 SLC4A7 TMEM133
Ever taken oral contraceptive pill 1.83 1 0 0.0 0.00 1.0e+00 TSPY26P
Medication: Blood pressure 10.44 10 7 21.2 -0.98 1.8e-07 ACE ATP2B1 CLCN6 CSK FES RGS19 SH2B3 SIK2 SLC4A7 TMEM133
High cholesterol (Self-reported) 34.28 11 8 24.2 -0.68 2.1e-02 ABCG5 APOB CLCN6 EPOR FES PAFAH1B2 PDXDC2 PSRC1 RGS19 TMEM133 ZNF259
Medication: Bendroflumethiazide 6.90 7 3 9.1 -0.98 3.3e-05 ATP2B1 CSK FES SH2B3 SIK2 SLC4A7 TMEM133
Medication: Lisinopril 5.72 4 0 0.0 -0.99 4.8e-04 CSK SH2B3 SLC4A7 TMEM133
Medication: Atorvastatin 14.17 6 5 15.2 -1.00 2.6e-05 ABCG5 APOB EPOR PAFAH1B2 PSRC1 ZNF259
Illnesses of father: High blood pressure 7.71 8 1 3.0 -0.99 3.2e-06 ABCG5 ACE ATP2B1 CLCN6 FES SH2B3 SLC4A7 TMEM133
Ever smoked 1.77 2 0 0.0 0.00 1.0e+00 FES SH2B3
Basal metabolic rate 1.66 8 1 3.0 0.57 1.4e-01 CTC-228N24.3 EPOR PSRC1 RGS19 SH2B3 SLC4A7 TMEM133 TSPY26P
Leg fat percentage (left) 2.78 5 4 12.1 -0.68 2.1e-01 CLCN6 CTC-228N24.3 DNAJC11 PDXDC2 TSPY26P
Arm fat-free mass (left) 1.75 5 1 3.0 0.24 6.5e-01 EPOR PSRC1 SH2B3 SLC4A7 TSPY26P
Diastolic blood pressure, automated reading 11.32 11 6 18.2 -0.91 9.4e-05 ACE ATP2B1 CLCN6 CSK CTC-228N24.3 FES PVRIG SH2B3 SIK2 TMEM133 TSPY26P
Vascular/heart problems diagnosed by doctor 17.77 16 12 36.4 0.97 8.2e-11 ABCG5 ACE ATP2B1 CLCN6 CSK CTC-228N24.3 DNAJC11 FES PDXDC2 PVRIG RGS19 SH2B3 SIK2 SLC4A7 TMEM133 TSPY26P
Cholesterol lowering medication 16.84 7 6 18.2 -0.95 1.1e-03 ABCG5 APOB EPOR PAFAH1B2 PSRC1 RGS19 ZNF259
Pain experienced in last month 2.14 1 0 0.0 0.00 1.0e+00 SH2B3
Heart attack/myocardial infarction (self-reported) 4.84 3 1 3.0 0.00 1.0e+00 FES PSRC1 SH2B3
Deep venous thrombosis (DVT) (self-reported) 1.30 1 0 0.0 0.00 1.0e+00 SH2B3
Heart disease (siblings) 4.34 3 0 0.0 0.00 1.0e+00 FES PVRIG ZNF259
Pack years of smoking 1.38 1 0 0.0 0.00 1.0e+00 PDXDC2
Impedance of whole body 1.79 7 1 3.0 0.10 8.2e-01 CTC-228N24.3 PDXDC2 RGS19 SIK2 SLC4A7 TMEM133 TSPY26P
Leg fat mass (left) 1.97 4 2 6.1 -0.60 4.0e-01 CLCN6 DNAJC11 PDXDC2 TSPY26P
Arm predicted mass (left) 1.75 6 2 6.1 0.31 5.0e-01 EPOR PSRC1 RGS19 SH2B3 SLC4A7 TSPY26P

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 2 0.0573 1.69
GTEx Adipose Visceral Omentum 1 0.0491 1.68
GTEx Adrenal Gland 2 0.1373 1.75
GTEx Artery Aorta 5 0.1680 1.73
GTEx Artery Coronary 0 0.0000 1.64
GTEx Artery Tibial 6 0.1595 1.74
GTEx Brain Caudate basal ganglia 0 0.0000 1.57
GTEx Brain Cerebellar Hemisphere 2 0.1343 1.71
GTEx Brain Cerebellum 2 0.1009 1.75
GTEx Brain Cortex 0 0.0000 1.76
GTEx Brain Frontal Cortex BA9 0 0.0000 1.70
GTEx Brain Hippocampus 0 0.0000 1.61
GTEx Brain Hypothalamus 0 0.0000 1.56
GTEx Brain Nucleus accumbens basal ganglia 0 0.0000 1.73
GTEx Brain Putamen basal ganglia 1 0.1603 1.55
GTEx Breast Mammary Tissue 0 0.0000 1.66
GTEx Breast Mammary Tissue (Male) 0 0.0000 1.63
GTEx Breast Mammary Tissue (Female) 0 0.0000 1.65
GTEx Cells EBV-transformed lymphocytes 0 0.0000 1.58
GTEx Cells Transformed fibroblasts 4 0.0953 1.71
GTEx Colon Sigmoid 1 0.0684 1.62
GTEx Colon Transverse 1 0.0484 1.68
GTEx Esophagus Gastroesophageal Junction 0 0.0000 1.72
GTEx Esophagus Mucosa 3 0.0904 1.71
GTEx Esophagus Muscularis 2 0.0619 1.70
GTEx Heart Atrial Appendage 0 0.0000 1.68
GTEx Heart Left Ventricle 0 0.0000 1.60
GTEx Liver 2 0.2789 1.66
GTEx Lung 2 0.0696 1.77
GTEx Muscle Skeletal 3 0.1038 1.75
GTEx Nerve Tibial 1 0.0231 1.60
GTEx Ovary 0 0.0000 1.74
GTEx Pancreas 1 0.0613 1.66
GTEx Pituitary 0 0.0000 1.67
GTEx Prostate 0 0.0000 1.74
GTEx Skin Not Sun Exposed Suprapubic 2 0.0813 1.69
GTEx Skin Sun Exposed Lower leg 4 0.1099 1.72
GTEx Small Intestine Terminal Ileum 0 0.0000 1.66
GTEx Spleen 0 0.0000 1.63
GTEx Stomach 2 0.1376 1.78
GTEx Testis 1 0.0317 1.67
GTEx Thyroid 3 0.0750 1.72
GTEx Uterus 0 0.0000 1.60
GTEx Vagina 2 0.3150 1.84
GTEx Whole Blood 2 0.1004 1.72
METSIM Adipose 2 0.0434 1.56
NTR Blood 0 0.0000 1.65
ROSMAP Brain Pre-frontal Cortex 4 0.0911 1.70
YFS Blood 6 0.1299 1.60
CommonMind Brain Pre-frontal Cortex 8 0.1488 1.63
TCGA Breast Tumor 1 0.1304 1.53
TCGA Breast Normal 4 0.0951 1.54
TCGA Ovarian Tumor 4 0.1369 1.59
TCGA Prostate Tumor 5 0.1446 1.61